Key Highlights

  • SciSparc (NASDAQ:SPRC) traded at USD 0.80, down 37.98%, in pre-market trading on Tuesday, October 27, 2026, after a Form 6-K of Monday, October 26, 2026 repriced warrants during its shift from cannabinoid medicines to agentic AI.
  • Stratum Holdings (NASDAQ:SRTM) traded at USD 0.2580, down 14.00%, as two non-binding letters of intent, one to sell its real estate businesses and one on offshore data centre assets, carry its move into GPU leasing.
  • Onconetix (NASDAQ:ONCO) traded at USD 0.3455, down 13.43%, after a reverse split notice, with a share exchange for Realbotix LLC meant to turn a diagnostics business into a humanoid robotics operation.
  • SANGRIX (NASDAQ:SGRX) traded at USD 0.3831, down 5.08%, with no company-specific announcement dated on the day, while its path from digital assets to AI infrastructure waits on the delivery of GPU servers.

SciSparc (NASDAQ:SPRC): cannabinoid medicines turn to agentic AI

SciSparc (NASDAQ:SPRC), an Israeli clinical-stage pharmaceutical and intellectual property company focused on cannabinoid-based technologies, traded at USD 0.80 in a pre-market snapshot, which implies a prior close of about USD 1.29 by simple arithmetic. A Form 6-K filed on Monday, October 26, 2026 disclosed an inducement offer letter under which one warrant holder agreed to exercise warrants over up to 405,728 ordinary shares for cash at USD 1.00 per share, against the original USD 4.929. Gross proceeds are expected at about USD 405,728, with closing on or about Tuesday, October 27, 2026. The filing reported no operating results or cash balance.

Here the pivot reaches the shares as a financing event. The company announced a transformation into agentic AI powered technologies on Thursday, October 15, 2026 and a focus on AI cybersecurity and finance on Monday, October 19, 2026. An inducement lowers the exercise price of existing warrants in return for immediate cash exercise, which adds shares to the float at a discount. The fall appears consistent with dilution, an inference. The cannabinoid pipeline continues through NeuroThera Labs, which completed batch release for the SCI-110 Phase IIb Tourette trial on Thursday, October 22, 2026, and the company values its stake of about 44.6% in NeuroThera near CAD 30 million. Named risks are repeated dilution and execution in a new business model.

Stratum Holdings (NASDAQ:SRTM): property services meet GPU leasing

Stratum Holdings (NASDAQ:SRTM), a company with residential real estate brokerage, franchising, property management and title operations that is repositioning towards artificial intelligence infrastructure and graphics processing unit (GPU) leasing, traded at USD 0.2580 in a pre-market snapshot. The company's release of Monday, October 26, 2026 at 7:30 a.m. ET described a non-binding letter of intent with Ocean Power Technologies to demonstrate renewable-powered offshore data centre assets. Stratum would provide GPU assets, integration expertise and a monthly retainer, while Ocean Power Technologies would provide a limited patent licence and prototype PowerBuoy assets. The cooling benefit is described as undemonstrated.

At this name the pivot begins with a disposal. The release of Monday, October 19, 2026 announced a non-binding letter of intent to sell substantially all assets of the legacy real estate businesses and the company targets profitability in 2027. Closing is subject to due diligence, a definitive agreement, approvals and lien releases. Market data show fiscal 2025 revenue of USD 68.51 million and a net loss of USD 32.82 million, with a first-half 2026 net loss of USD 15.6 million, which was 9.4% narrower. Those figures relate to operations that the sale would remove. Risks are failure to sign definitive agreements, dilution from financing GPU purchases and liquidity, since market data indicate roughly 553,000 shares outstanding.

Onconetix (NASDAQ:ONCO): diagnostics and a humanoid robotics exchange

Onconetix (NASDAQ:ONCO), a commercial-stage oncology company that owns the Swiss prostate cancer diagnostics business Proteomedix, traded at USD 0.3455 in a pre-market snapshot. The company's release of Monday, October 26, 2026 announced board approval of a 1-for-10 reverse stock split, expected to take effect on Friday, November 6, 2026, which would cut common shares from about 5,886,774 to about 588,677. A reverse split consolidates shares to raise the quoted price without changing the value of each holder's stake. The decline appears consistent with the usual market reaction, which is an inference.

The pivot runs through a share exchange agreement to acquire all equity of Realbotix LLC, a humanoid robotics operation, for stock, subject to shareholder and regulatory approvals. The release of Friday, October 23, 2026 added USD 500,000 of bridge financing, bringing principal outstanding to USD 3,000,000 of a facility of up to USD 5,000,000, and interest of 12% a year accrues if the agreement terminates. The Form 10-Q for the quarter ended June 30, 2026 reported revenue of USD 17,120, a net loss of USD 2,867,303 and cash of about USD 5.9 million, and it states substantial doubt about continuing as a going concern. Realbotix Corp reported third quarter revenue of USD 354,000, against USD 595,000 a year earlier.

SANGRIX (NASDAQ:SGRX): a digital asset holder builds an AI server project

SANGRIX (NASDAQ:SGRX), a Singapore-based company formerly named Bit Origin, traded at USD 0.3831 in a pre-market snapshot. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The release of Friday, October 16, 2026 moved delivery of 16 servers holding 128 NVIDIA B300 GPUs in Malaysia to the week of Tuesday, November 3, 2026, later than the third quarter of 2026 previously expected. The decline appears consistent with thin liquidity and the delayed timetable, an inference.

The company's releases contain no revenue, earnings or cash figures, so the available financial data are transaction-level. It sold 3,000,000 Dogecoin on Monday, September 7, 2026 at a weighted average price of about USD 0.0892 per coin, for gross proceeds of about USD 267,665 for working capital and deployment costs. The project is described as an approximately USD 11 million acquisition, large against a market capitalisation of roughly USD 0.8 million on recent market data. About one further week is needed after delivery for inspection and testing. Risks are further delay and funding through asset sales.

Where Things Stand

The answer is that none of the four pivots is complete, and each reaches the shares through a different channel. SciSparc (NASDAQ:SPRC) shows the financing channel, with a warrant repricing that coincided with a 37.98% fall. Stratum Holdings (NASDAQ:SRTM) shows the disclosure channel, since both of its letters of intent are non-binding. Onconetix (NASDAQ:ONCO) shows the capital structure channel, through a consolidation and a going concern warning, while SANGRIX (NASDAQ:SGRX) shows the execution channel, because revenue cannot start before the servers are racked.

The next catalysts are the expected closing of the SciSparc exercise on or about Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026, which follows the rate rise to 4.00% from 3.75% on Wednesday, September 16, 2026, the SANGRIX server delivery in the week of Tuesday, November 3, 2026 and the Onconetix split on Friday, November 6, 2026. Definitive agreements at Stratum Holdings carry no stated date. Pre-market prices are snapshots and can change before the open, and this is not investment advice.